跳至主要内容
临床试验/NCT00735774
NCT00735774已完成1 期

Suitability of 11C-ORM-13070 as a Positron Emission Tomography Tracer; an Open Study in Healthy Males

Orion Corporation, Orion Pharma1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2008年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
18
试验地点
1
主要终点
Suitability of 11C-ORM-13070 as a PET tracer

研究概览

简要总结

The purpose of the study is to evaluate the suitability of 11C-ORM-13070 as a positron emission tomography tracer.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Good general health ascertained by detailed medical history and physical examination
  • Males between 18 and 45 years
  • Body mass index (BMI) between 18-30 kg/m2
  • Weight 55-95 kg (inclusive)

排除标准

  • Evidence of clinically significant cardiovascular, renal, hepatic, haematological, gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator
  • Any condition requiring regular concomitant medication including herbal products or likely to need any concomitant medication during the study.
  • Regular consumption of more than 21 units of alcohol per week (1 unit = 4 cl spirits, about 13 g of alcohol)
  • Current use of nicotine-containing products more than 5 cigarettes or equivalent/day
  • Inability to refrain from using nicotine-containing products during the stay in the study centre
  • Inability to refrain from consuming caffeine-containing beverages during the stay in the study centre e.g. propensity in getting headache when refraining from caffeine-containing beverages
  • Blood donation or loss of significant amount of blood within 3 months prior to the screening visit
  • Abnormal 12-lead electrocardiogram (ECG) finding of clinical relevance
  • Any abnormal value of laboratory, vital signs, or physical examination, which may in the opinion of the investigator interfere with the interpretation of the test results or cause a health risk for the subject if he takes part into the study
  • Anatomical abnormality in MRI which may in the opinion of the investigator interfere with the interpretation of PET results
  • Participation in a drug study within 3 months prior to the entry into this study
  • Participation in a prior PET study

研究组 & 干预措施

11C-ORM-13070

Experimental

干预措施: 11C-ORM-13070 (Drug)

结局指标

主要结局

Suitability of 11C-ORM-13070 as a PET tracer

时间窗: 1 day

次要结局

未报告次要终点

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验